Get the Stockscreener App
3.26
6.54%
0.20
After Hours:
3.24
-0.02
-0.61%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.26, with a volume of 4.09M.
It is up +6.54% in the last 24 hours and down -2.10% over the past month.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.06
Open:
$3.06
24h Volume:
4.09M
Relative Volume:
1.03
Market Cap:
$633.60M
Revenue:
$41,000
Net Income/Loss:
$-88.09M
P/E Ratio:
-3.2106
EPS:
-1.0154
Net Cash Flow:
$-67.55M
1W Performance:
+23.95%
1M Performance:
-2.10%
6M Performance:
-17.26%
1Y Performance:
-35.19%
1-Day Range:
$3.04
$3.26
1-Week Range:
$2.56
$3.26
52-Week Range:
$2.56
$7.73
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.26 | 594.73M | 41,000 | -88.09M | -67.55M | -1.0154 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Upgrade | Goldman | Sell → Neutral |
| Mar-18-26 | Initiated | Truist | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - The Manila Times
May 13: Altimmune to post Q1 results, give business update - Stock Titan
LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune catalysts: 2026 data readouts and financing risks - MSN
MSN Money - MSN
Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com Nigeria
Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com
Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan
Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan
Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan
Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan
Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan
Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan
[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan
Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan
RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan
Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan
Dilution fears return: Why ALT stock is getting hit again - MSN
ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan
ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView
Altimmune a new buy at Truist on pemvidutide promise - MSN
ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN
Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union
Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter
Altimmune closes $225M financing for MASH drug trial - Investing.com UK
Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals
Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz
Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail
Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan
Altimmune prices $75M direct offering - MSN
Altimmune shares slide after $75 million registered direct offering - MSN
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):